NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-
testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit …

T cell-based adoptive immunotherapy has been shown to be a promising treatment for
various types of cancer. However, adoptive T cell therapy currently requires the custom …

The most frequent subtype of acute myeloid leukemia (AML) is defined by mutations in the
nucleophosmin 1 (NPM1) gene. Mutated NPM1 (ΔNPM1) is an attractive target for …

The transfer of T cell receptor (TCR) genes can be used to induce immune reactivity toward
defined antigens to which endogenous T cells are insufficiently reactive. This approach …

Single and dual amino acid substitution variants were generated in the TCR CDRs of three
TCRs that recognize tumor-associated Ags. Substitutions that enhance the reactivity of TCR …

T cell receptor (TCR)-based adoptive T cell therapies (ACT) hold great promise for the
treatment of cancer, as TCRs can cover a broad range of target antigens. Here we …

T cell receptor (TCR)–based therapy has the potential to induce durable clinical responses
in patients with cancer by targeting intracellular tumor antigens with high sensitivity and by …

Genetic engineering of T lymphocytes is an attractive strategy to specifically redirect T-cell
immunity toward viral infections and malignancies. We previously demonstrated redirected …

The function of T-cell receptor (TCR) gene modified T cells is dependent on efficient surface
expression of the introduced TCR α/β heterodimer. We tested whether endogenous CD3 …

Major limitations of currently investigated αβT cells redirected against cancer by transfer of
tumor-specific αβTCR arise from their low affinity, MHC restriction, and risk to mediate self …